Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no enhancer at all. Bioavailability is the whole story here - roughly one per cent for oral semaglutide, and highly sensitive to water volume and fasting window.
I am asking mechanistically rather than practically — I want the model, not the protocol. I want to know what the trade-off actually is rather than which option is…
The clinician who ordered the panel was not concerned; I would still like to understand it. This is one of those things that everyone repeats and nobody derives. This…
The case in front of me: PIONEER-1 · tirzepatide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at…
I understand in general terms that peptides do not survive oral administration - stomach acid, proteases, and a wall of epithelium that evolved specifically to keep…
Orforglipron is described as a non-peptide oral GLP-1 receptor agonist, which I take to mean it is a conventional small molecule rather than a peptide with a delivery…
I have photographs before and after reconstitution if the visual detail matters. I keep seeing this stated as a fact with no explanation attached, and unexplained…
This matters because it predicts what a related molecule should do. This is one of those things that everyone repeats and nobody derives. This matters practically,…
I keep seeing people reason like this: oral semaglutide 14 mg daily is 98 mg a week, injectable is 2.4 mg a week, therefore the oral dose is roughly 40 times higher,…
I would like to know how much of this is established and how much is a reasonable story. I want to know what the trade-off actually is rather than which option is…
SOUL tested oral semaglutide 14 mg daily in people with type 2 diabetes and either atherosclerotic cardiovascular disease or chronic kidney disease, and reported a…
The specifics, since they change the answer: liraglutide · mazdutide. I am trying to choose between two options that are usually discussed as though only one exists.…
Details up front: SURPASS-2 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
Stated plainly: SURPASS-3 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Conditions: ecnoglutide · SURMOUNT-1. This is one of those things that everyone repeats and nobody derives. This matters practically, not just academically, because…
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL Biochem